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Abstract
Background: Carbonic anhydrase IX (CAIX) is a membranous expressed metalloenzyme involved in pH
homeostasis and cell adhesion. The protein is overexpressed in a variety of tumors and potentially associated with
negative outcome. This study was designed to investigate the prognostic role of CAIX in serum and tumor tissue
of patients with primary cervical cancer.
Methods: Tumor samples of 221 consecutive patients with primary cervical cancer who underwent surgery
between 1993 and 2008 were analyzed for CAIX expression by immunohistochemistry. Additionally, preoperative
serum CAIX concentrations were determined by ELISA in a subset of patients. Correlation with intratumoral CAIX
expression as well as clinicopathological factors and outcome was analyzed.
Results: CAIX expression was observed in 81.9% of the tumor specimens; 62.0% showed a moderate or strong
staining intensity. Moderate/strong expression was associated with squamous histology (p = 0.024), advanced
tumor stage (p = 0.001), greater invasion depth (p = 0.025), undifferentiated tumor grade (p < 0.001) and high
preoperative SCC-Ag values (p = 0.042). Furthermore patients with moderate/strong intratumoral CAIX expression
had a higher number of metastatic lymph nodes compared to those with none/weak intratumoral expression
levels (p = 0.047) and there was a non-significant association between high intratumoral CAIX expression and
shorter survival (p = 0.118). Preoperative serum concentrations of CAIX ranged between 23 and 499 pg/mL and
did not correlate with intratumoral expression or other clinicopathological variables.
Conclusion: CAIX is associated with advanced tumor stages and lymph node metastases in cervical cancer,
potentially representing a new target in this disease. In contrast to other epithelial cancers we could not observe a
correlation between serum CAIX and its intratumoral expression.
Background
Altered glycolysis is one of the crucial characteristics of
cancer cells [1]. While normal cells can suppress the
conversion of pyruvate to lactic acid in the presence of
oxygen, cancer cells bypass oxidative phosphorylation in
mitochondria for ATP production. The intracellular lac-
tate excess results in acidification of the extracellular
space and upregulation of acid-controlling proteins like
carbonic anhydrases [2]. They catalyze the hydration of
CO2 to HCO3 and play a central role in pH homeostasis
[3,4]. Carbonic anhydrase IX (CAIX) is one of the mem-
bers of this enzyme family; apart from its role in the pH
regulation, CAIX has a function in cell adhesion and is
important for growth and survival of tumor cells [5-7].
CAIX expression is induced by hypoxia through stabili-
zation of the transcription factor HIF-1a [8]. In normal
tissue, expression of CAIX is very limited, low levels
have been detected in gastric cells, the epithelium of the
gall bladder, pancreatic ducts or in crypt cells of the
small intestine [9]. Despite its sparse expression in nor-
mal tissue, CAIX is overexpressed in a variety of solid
tumors [10]. High levels of CAIX were found to be asso-
ciated with unfavourable patient outcome in several
epithelial cancers [11-14]. In renal cell cancer, overex-
pression of CAIX is common and the possible role of
CAIX targeting antibodies (WX-G250, Rencarex
®)i s
currently evaluated in phase III trials [15].
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CAIX, there is a soluble isoform that is released by pro-
teolytic cleavage and can be detected in the serum [16].
This form of CAIX could serve as an easily accessible
marker to stratify patients for therapy and monitor
response. Information regarding the soluble form of
CAIX is very limited [17]. There are studies on serum
CAIX in renal cell cancer patients showing significantly
higher concentrations in patients with metastatic disease
than in patients with localized cancer [16,18]. Further-
more, renal cell cancer patients with high serum CAIX
before surgery appear to be at significantly higher risk
for disease recurrence than those with low preoperative
values [18]. Other authors could show that CAIX was
cleared from serum after complete tumor resection, sug-
gesting a very promising marker to monitor therapy
response and disease recurrence [16]. In vulvar cancer
we could demonstrate similar results: Preoperative
serum CAIX levels correlated with intratumoral CAIX
expression and high values were prognostic for unfa-
vourable outcome [19].
Cervical cancer is the third most common cause of
cancer-related death in women accounting for approxi-
mately 500,000 new cases and 280,000 deaths worldwide
each year [20]. Currently established prognostic factors
include International Federation of Gynecology and
Obstetrics (FIGO) stage, tumor volume, lymphatic
spread, human papilloma virus (HPV) type 18 infection,
invasion depths and vasculars p a c ei n v a s i o n[ 2 1 - 2 3 ] .
Although these prognostic factors are well established,
the biological factors associated with recurrence and
survival remain largely unknown and treatment options
for recurrent or advanced disease are limited especially
in patients already treated with radiochemotherapy. The
identification of new prognostic factors and markers for
therapy monitoring is therefore of high clinical rele-
vance. In daily routine, serum Squamous Cell Cancer
Antigen (SCC-Ag) is often used to monitor therapy of
advanced disease [24]. Its value as a sensitive and speci-
fic tumor marker has been previously demonstrated
[24-26]. The role of CAIX in cervical cancer has not
been fully determined. Overexpression is potentially
associated with a higher rate of lymph node metastases
and with negative prognosis [27-29]. Serum CAIX could
therefore be of clinical relevance for prognosis and ther-
apy monitoring in cervical cancer. However, information
on serum CAIX in cervical cancer is not available.
To gain insight into the role of intratumoral and
serum CAIX in cervical cancer, we determined CAIX
expression and its prognostic relevance in correlation
with preoperative CAIX serum concentrations and other
clinicopathological factors as well as survival in patients
with primary cervical cancer.
Methods
Patients
Tumor tissue from 221 patients undergoing surgery for
primary cervical cancer at 4 different institutions
between 1993 and 2008 was analyzed. Detailed patient
characteristics are listed in Table 1. In addition, 46 preo-
perative serum samples from a subset of the included
patients were analyzed. Serum samples were not routi-
nely taken from all included patients before surgery but
on a voluntary basis in one of the participating centers.
To assure the analysis of a representative collective,
FIGO stages were compared to those of the whole
cohort showing a similar stage distribution (FIGO stage
Ib1 52.2%, Ib2 13.0%, IIa 6.5%, IIb 17.4%, III 0.0%, IVa
4.3%, IVb 6.5%, compare Table 1). Clinicopathologic fac-
tors were evaluated by reviewing medical charts and
pathologic reports. For tumor staging, 6
th edition UICC
TNM classification and stage groupings were used [30].
Informed consent for the scientific use of patient data,
tumor tissue and serum had been obtained from all
patients in coordination with the local ethics committee
according to the principles of the declaration of Helsinki
(Ethics committee of the Medical Board Hamburg, refer-
ence number #190504). In the current study, all data
were analyzed anonymously.
For 180 patients detailed therapy information and for
175 patients detailed follow-up data from the date of
primary surgery to the date of death or last contact (July
2009) were available. The treatment of cervical cancer
during the investigational period consisted of radical
hysterectomy and resection of the pelvic and paraaortic
lymph nodes via laparotomy for FIGO stages I and II.
Only in stage Ia and Ib disease with fertility preserving
objective radical hysterectomy was omitted. Adjuvant
radio/chemotherapy of the pelvis and the paraaortic
region was performed in case of advanced disease
according to effective German Guidelines [31]. For
FIGO stage III and IV cervical cancer primary radio/
chemotherapy was generally recommended. In our
study, 24 patients were included with FIGO stage III/IV
disease who received primary surgery. Those patients
underwent surgery either to prevent further tumor inva-
sion of the bladder and/or rectum or were not classified
as FIGO III/IV until surgery (predominantly in case of
paraaortic lymph node metastases).
CAIX Immunohistochemistry
To analyze the tissue-expression of CAIX, we performed
immunohistochemistry (IHC) with paraffin embedded
tumors from all included patients, using a commercially
available CAIX IHC kit (Oncogene Science, Cambridge,
Mass 0214, USA) according to the manufacturer’s
instructions. Tissue sections were cut at a thickness of 5
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Germany), dewaxed with Xylene and gradually hydrated.
Afterwards a peroxidase blocking solution was applied
and sections were incubated at room temperature for 5
minutes followed by several washings in phosphate buf-
fered saline (PBS) (CA IX IHC Kit, Reagent H). Adja-
cent all sections were probed with the primary mouse
anti-CA IX antibody (prediluted at 0.5 μg/mL, CA IX
IHC Kit, Reagent B) incubating them at room tempera-
ture for 30 minutes. After several washings in PBS,
slides were covered with the biotinylated secondary anti-
body (CA IX IHC Kit, Reagent C) for 10 minutes,
washed several times and incubated with HRP-labeled
streptavidin (CA IX IHC Kit, Reagent D) for another 10
minutes to be washed three times again. Finally the
DAB substrate-chromogen solution (CA IX IHC Kit,
Reagent F1, F2 and F3) was applied for 5 minutes fol-
lowed by washings in Aqua dest. The slides were briefly
counterstained with haematoxylin (CA IX IHC Kit,
Reagent G) and dehydrated before mounting.
The IHC staining was evaluated independently by
two gynecopathologists using the immunoreactive
Table 1 Patient characteristics (n = 221)
(%)
Age (years)
Median 47
Mean 49
Range 23 - 85
Histological subtype (n = 221)
Squamous cell carcinoma 161 (72.9)
Adenocarcinoma 35 (15.8)
Adenosquamous cell carcinoma 25 (11.3)
Tumor stage (FIGO) (n = 221)
Ia1 0 (0.0)
Ia2 3 (1.4)
Ib1 113 (51.1)
Ib2 20 (9.0)
IIa 17 (7.7)
IIb 44 (19.9)
IIIa 0 (0.0)
IIIb 1 (0.5)
IVa 7 (3.2)
IVb 16 (7.2)
Lymph node involvement (n = 221)
N0 168 (76.0)
N1 53 (24.0)
Removed lymph nodes (n = 221)
Median 27
Mean 30
Range 2 - 88
Affected lymph nodes (n = 53)
Median 2
Mean 3
Range 1 - 14
Distant metastasis (n = 181)
M0 165 (91.2)
M1 16 (8.8)
Tumor grade (n = 215)
G1 9 (4.2)
G2 95 (44.2)
G3 111 (51.6)
Lymphovascular space invasion (n = 196)
L0 64 (32.7)
L1 132 (67.3)
Vascular invasion (n = 169)
V0 151 (89.3)
V1 18 (10.7)
Surgical therapy (n = 181)
Radical hysterectomy 180 (99.5)
Trachelectomy 1 (0.5)
Preoperative SCC serum concentration (μg/l) (n = 144)
Median value 1.4
Mean 5.2
Range 0.2 - 107.0
Table 1 Patient characteristics (n = 221) (Continued)
Adjuvant Therapy (n = 180)
No therapy 88 (48.9)
Adjuvant radiotherapy 44 (24.4)
Adjuvant concomitant chemoradiotherapy 48 (26,7)
Follow-up (months) (n = 175)
Median 49
Mean 63
Range 2-193
Disease free surviving 131 (74.9)
Disease recurrence 44 (25.1)
Died of disease 38 (21.7)
CAIX expression (IRS) (n = 221)
Median expression 2
Mean 3
Range 0 - 12
IRS 0 40 18.1
IRS 1 44 19.9
IRS 2 35 15.8
IRS 3 9 4.1
IRS 4 32 14.5
IRS 6 29 13.1
IRS 8 2 0.9
IRS 9 23 10.4
IRS 12 7 3.2
CAIX serum concentration (pg/mL) (n = 46)
Median concentration 104
Mean 137
Range 23-499
IRS: Immunoreactive score (IRS) according to W. Remmele and H. E. Stegner.
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Stegner as product of staining intensity (graded 0-3)
and percentage of positive cells (graded 0-4, 0: 0%, 1:
<10%, 2: 10-50%, 3: 51-80%, 4: >80%) resulting in a
score from 0-12 [32].
Quantitative analysis of serum CAIX level
CAIX was quantified by a commercially available ELISA
(Oncogene Science, Cambridge, Mass 0214, USA). Con-
trol samples consistent of purified CAIX protein in buf-
fer with low, medium and high concentrations as
included in the ELISA kit ("MN/CAIX ELISA controls”).
Serum samples and controls were diluted 1:2 with sam-
ple diluting buffer (containing bovine serum albumin,
mouse IgG, buffer salts and 0.09% sodiumazide). One
hundred microliters of the standards, of diluted control
samples and of diluted serum samples were dispensed
into the wells of a 96-well plate (coated with the mono-
clonal capture antibody) and incubated for two hours at
room temperature on a shaker at 800 rpm. Wells were
washed, and 100 μl of the detection antibody (contain-
ing biotinylated anti-CAIX antibody) was added. The
plates were incubated for 30 min at room temperature,
washed, and then further incubated with 100 μlo fa
streptavidin-HRP (horseradish peroxidase) conjugate for
30 min at room temperature. After washing, 100 μlo f
chromogenic substrate (TMB blue substrate) was added
for 30 min at room temperature. The reaction was
stopped with 100 μl of 2.5 N sulphuric acid and absor-
bance was read at 450 nm by an automated plate reader
(Tecan, Crailsheim, Germany). The CAIX concentration
was estimated from the standard curve. Each sample,
standard, and control was analyzed in duplicate.
Statistics
All statistical analyses were conducted using the R open
source statistical software package [33]. p-values < 0.05
were considered statistically significant. In accordance
with previously published data on CAIX expression in
epithelial tumors we analyzed CAIX expression in a two
class system, merging IRS score 0 and 1 into one class
corresponding with none/weak CAIX expression levels
and IRS score 2 - 12 into another class corresponding
with moderate/strong intratumoral CAIX expression
[19,34,35]. Mann-Whitney-U-Tests and Fisher’se x a c t
tests were used to calculate correlations between CAIX
expression, serum CAIX and clinicopathological para-
meters. Kaplan-Meier analyses of overall and disease-
free survival were performed. The log rank test was
applied to examine the relationship between serum
CAIX, intratumoral CAIX expression and survival.
Additionally, we performed a stratified log rank test,
comparing CAIX effects on survival in patients with
FIGO stage I and FIGO stage II-IV disease, to
investigate potential stage dependant differences. The
Cox Proportional Hazard Model was used for multivari-
ate analyses.
Results
Patients
A total of 221 patients were included in this study;
detailed characteristics are listed in Table 1. For
180 patients detailed therapy information and for
175 patients detailed follow-up data were available. All
patients underwent radical surgery. No further treat-
ment was initiated in 88 patients (48.9%), whereas
92 (51.1%) patients received adjuvant radio- and/or che-
motherapy. The predominantly applied chemotherapy
regimen was cisplatin as a single agent, 4 patients
received a cisplatin based combination therapy. Median
follow-up time was 49 months. At the time of last fol-
low-up, 131/175 (74.9%) patients were alive and without
relapse whereas 38/175 (21.7%) patients had died from
t h ed i s e a s e .I nc a s eo fd i s e a s er e c u r r e n c e( n=4 4 ) ,
relapse was locoregional in 10 patients, distant in
13 patients and both in 18 patients (3 cases unknown).
CAIX immunohistochemistry
A total of 221 tumor samples were stained for determi-
nation of CAIX expression. CAIX was detectable in 181
(81.9%) of all specimens. 137 (62.0%) samples exhibited
a moderate or strong (score 2-12) staining result (Table 1).
Figure 1 shows representative tumor samples with none/
weak/moderate/strong CAIX expression. CAIX protein
expression was always membranous. Tumor associated
stromal cells as well as inflammatory cells stained nega-
tive for CAIX. Table 2 summarizes the correlation of
CAIX expression with clinicopathological parameters.
Moderate/strong expression was associated with squa-
mous histology (p = 0.024), advanced FIGO and pT
stage (p = 0.013 and p = 0.001), greater invasion depth
(p = 0.025), undifferentiated tumor grade (p < 0.001) and
high preoperative SCC-Ag concentration (p = 0.042).
Furthermore, patients with moderate/strong intratumoral
CAIX expression had a higher number of metastatic
lymph nodes compared to those with none/weak intratu-
moral expression levels (p = 0.047). Fifteen (11.0%) of
the patients with moderate/strong intratumoral CAIX
expression showed three or more lymph node metastases
whereas in only 2 cases (2.4%) with none/weak CAIX
expression three or more positive lymph nodes were
diagnosed. We could not demonstrate an association
between CAIX expression and lymphovascular space
invasion or patients’ age. There was an association
between none/weak intratumoral CAIX expression and
longer survival; however, this result failed to reach statis-
tical significance (overall survival p = 0.118, Figure 2; dis-
ease-free survival p = 0.220, not shown). The potential
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expression on survival did not significantly differ between
FIGO stages I and II-IV in a stratified survival analysis
(disease-free survival p = 0.580, overall survival p =
0.331, not shown).
Serum CAIX
Median preoperative serum CAIX was 104 pg/mL
(mean 137.0, range 23-499 pg/mL). Patients with a mod-
erate/strong intratumoral CAIX expression did not show
significantly higher serum concentrations (median 110
pg/mL, range 23-499 pg/mL) compared to patients with
none/weak expression (median 91 pg/mL, range 27-257
pg/mL, p = 0.466). Furthermore, serum CAIX did not
show any association with the analyzed clinicopathologi-
cal factors (tumor stage, lymph node involvement, lym-
phovascular space invasion, invasion depth, tumor
grade, histological type, preoperative serum SCC-Ag).
Nevertheless, there was a non-significant association
between high preoperative serum CAIX and shorter
disease-free survival (disease-free survival p = 0.127,
Figure 3; overall survival p = 0.320, not shown). After
stratifying for FIGO stages, the negative effect of a
serum CAIX above median on survival was especially
distinct in patients with FIGO stage I disease (disease-
free survival p = 0.051, Figure 4; overall survival p =
0.059, not shown)
Multivariate analysis
The independent prognostic impact of intratumoral
CAIX expression and preoperative serum CAIX for dis-
ease-free and overall survival adjusted for tumor stage
(FIGO), pN, tumor grade and depth of invasion was
analyzed using the Cox Proportional Hazard Model.
Higher FIGO stage and nodal involvement were shown
to be independent prognostic factors for decreased sur-
vival. Neither moderate/strong CAIX expression nor
serum CAIX above median before surgery could be
demonstrated independently relevant for prognosis in
this patient cohort.
Discussion
In this study we analyzed the prognostic relevance of
CAIX in tumor tissue of 221 and sera of 46 patients
Figure 1 CAIX IHC: none (A, IRS 0), weak (B, IRS 1), moderate (C, IRS 4) and strong (D, IRS 12) expression.
Woelber et al. BMC Cancer 2011, 11:12
http://www.biomedcentral.com/1471-2407/11/12
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study on CAIX expression in cervical cancer and the
first study investigating the role of serum CAIX for this
tumor entity. The high number of samples in combina-
tion with survival data enables a comprehensive survey
of CAIX expression with respect to multiple clinico-
pathological parameters.
More than 80% of the patient samples stained positive
for CAIX (62% with moderate/strong intensity). This
expression rate confirms previously published results: In
a study by Loncaster et al, expression was found in 79%
of the samples [13,36]. Tumor associated stromal cells
as well as inflammatory cells stained negative for CAIX.
In our analysis, moderate/strong intratumoral CAIX
expression was significantly associated with advanced
tumor stages, a higher depth of invasion, undifferen-
tiated tumor grade as well as higher preoperative serum
SCC levels. Furthermore, there was a strong correlation
of CAIX expression to the number of positive locoregio-
nal lymph nodes. All of these features are well known to
be associated with unfavorable clinical outcome [21,22].
These results are confirmed by published results from
smaller studies on CAIX expression in cervical cancer
[27-29]. Up-regulation of CAIX is probably an adapta-
tion to aerobic glycolysis in tumor cells for maintenance
of the intracellular pH in advanced carcinomas. Acidifi-
cation of extracellular space by this mechanism may
contribute to tumor cell invasion and development of
metastases [37,38]. High levels of CAIX may therefore
promote the development of locoregional lymph node
metastases. In our study we also found an association
between moderate/strong intratumoral CAIX expression
and shorter survival. The effect was not significant, pos-
sibly because of a restricted number of patients with
advanced tumor stages and/or positive lymph nodes.
Taken together, enhanced expression of CAIX appears
to be an important feature of cancerogenesis in cervical
cancer.
Serum CAIX could therefore serve as an easily acces-
sible marker to stratify patients for therapy and monitor
response. While tumor tissue is usually only available at
surgery, serum is easily accessible during the whole
course of the disease. This is especially relevant in
patients that are not always treated with a primarily
Table 2 Correlations between CAIX expression and clinicopathological factors
Carbonic anhydrase IX expression p-value
none/weak moderate/strong
All samples (n = 221) 84 137
Histological subtype (n = 221) squamous 53 108 0.024
adenomatous 20 15
adenosquamous 11 14
FIGO stage (n = 221) I 62 74 0.013
II 15 46
III/IV 7 17
UICC tumor stage (n = 221) pT1 65 76 0.001
pT2 15 55
pT3/4 4 6
Nodal involvement (n = 221) pN0 69 99 0.106
pN1 15 38
Number of positive lymphnodes (n = 221) 0 69 99 0.047
1-3 13 23
>3 2 15
Tumor grade (n = 215) G1 9 0 <0.001
G2 32 63
G3 39 72
Lymphovascular space invasion (n = 196) L0 25 39 0.875
L1 49 83
Invasion depth in mm (n = 185)* median 12 (n = 70) 16 (n = 115) 0.025
Patients age in years (n = 221)* median 49.5 47.0 0.549
SCC-Ag in μg/L (n = 144)* median 1 (n = 55) 1.9 (n = 89) 0.042
Serum CAIX in pg/mL (n = 46)* median 91 (n = 17) 110 (n = 29) 0.466
Fisher’s exact test was used for categorical data, the Mann-Whitney-U-Test for continuous variables (*).
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Page 6 of 10Figure 2 Overall survival of patients with moderate/strong versus vs. none/weak intratumoral CAIX expression (p = 0.118, n = 175).
Figure 3 Disease-free survival of patients with Serum CAIX below and above the median of 104 pg/ml (p = 0.127, n = 40).
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cancer. Currently, detailed information on serum CAIX
as a biomarker is only available in renal cell cancer
patients: Serum CAIX has been shown to serve as a pro-
mising marker for therapy monitoring and prediction of
p r o g n o s i si np a t i e n t sw i t hc a n c e ro ft h ek i n d n e y[ 1 6 ] .
The marker is especially interesting as some groups
have reported a clearance of CAIX from serum after
complete tumor resection [16]. However, in a longitudi-
nal study on serum CAIX in ovarian cancer patients at
our institution, we could not observe a clearance of
CAIX from serum after surgery and chemotherapy [17].
To investigate the role of serum CAIX in cervical can-
cer we determined preoperative serum concentrations in
a subset of 46 patients. Patients in our study showed
CAIX serum concentrations between 23 and 499 pg/mL
with a mean of 137 pg/mL. Patients with renal cell car-
cinoma had similar concentrations in localized disease
though concentrations were measured using a different
assay (91.65 ± 13.29 pg/mL) [18]. In our own series on
preoperative serum CAIX in vulvar cancer analyzed by
the same assay, serum concentrations (range 56 and
8 7 9p g / m L ,m e a n2 3 7 . 2 9p g / m L )w e r ea b o v et h o s e
found in the current study despite mostly locally
restricted disease [19]. A defined cut-off level for normal
values of serum CAIX has not been determined yet and
conflicting results have been published concerning CAIX
serum levels in healthy males and females. In the series
of Li et al. mean serum CAIX level was significantly
higher in renal cell cancer patients than in healthy indivi-
duals (patients with metastatic renal cell cancer: mean
216.68 ± 67.02 pg/mL; patients with localized disease:
mean 91.65 ± 13.29 pg/mL and healthy individuals: mean
14.59 ± 6.22 pg/mL). In contrast to these findings, others
reported considerably higher levels in normal sera (mean
221 pg/mL in healthy females) [39].
Information regarding the relation of intratumoral
CAIX expression and detection of its soluble isoform is
very limited. A recently published study on CAIX expres-
sion and serum concentrations in renal cell cancer could
not demonstrate a correlation: Zhou et al. found serum
CAIX to be associated with tumor size but not with intra-
tumoral CAIX expression [40]. Possibly, intratumoral
hypoxia, increasing with tumor size, causes the soluble
form of CAIX to be released into bloodstream. In contrast
to these results, a study on urinary CAIX in renal cell can-
cer patients could demonstrate a coherence of soluble
CAIX and intratumoral CAIX expression [41]. Both stu-
dies are based on small patient numbers. In our previous
study on vulvar cancer, patients with high serum CAIX
showed a significantly higher intratumoral expression of
CAIX while the current study fails to proof this correla-
tion for cervical cancer. One possible explanation could
be the low proportion of patients with advanced disease.
Figure 4 Disease-free survival of patients with Serum CAIX below and above the median of 104 pg/ml stratified according to FIGO
stage (p = 0.051 and p = 0.919, n = 40).
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cancer patients is extremely limited. We observed a
non-significant association between high CAIX serum
concentrations before surgery and unfavourable disease-
free survival; this effect was especially seen in early stage
disease. Our findings are consistent with results on
CAIX serum concentrations in renal cell cancer: Li et al.
could demonstrate a decreased disease-free survival for
patients with high serum CAIX concentrations before
surgery [18]. However, in our longitudinal study on
serum CAIX in ovarian cancer patients, we could not
observe a prognostic relevance of preoperative serum
CAIX for survival [17].
Conclusions
CAIX overexpression is seen in a great proportion of
patients with cervical carcinoma and related to adverse
clinicopathological parameters as well as unfavorable out-
come. The exclusive expression of CAIX in cancer tissue
qualifies this protein as suitable target for therapeutic inter-
ventions. The role of serum CAIX in this context remains
uncertain; a detailed evaluation of this serum marker in
greater cohorts is highly desirable to clarify its clinical role.
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